211 related articles for article (PubMed ID: 24392688)
1. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.
Hirose W; Kato Y; Yamamoto T; Kassai M; Takata M; Hayashi S; Arai Y; Imai S; Yoshida K
Bioorg Med Chem Lett; 2016 Aug; 26(16):3866-9. PubMed ID: 27432763
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
4. A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core.
Duvey G; Perry B; Le Poul E; Poli S; Bonnet B; Lambeng N; Charvin D; Donovan-Rodrigues T; Haddouk H; Gagliardi S; Rocher JP
Bioorg Med Chem Lett; 2013 Aug; 23(16):4523-7. PubMed ID: 23850200
[TBL] [Abstract][Full Text] [Related]
5. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
6. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Bezard E; Pioli EY; Li Q; Girard F; Mutel V; Keywood C; Tison F; Rascol O; Poli SM
Mov Disord; 2014 Jul; 29(8):1074-9. PubMed ID: 24865335
[TBL] [Abstract][Full Text] [Related]
7. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
8. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
Grégoire L; Morin N; Ouattara B; Gasparini F; Bilbe G; Johns D; Vranesic I; Sahasranaman S; Gomez-Mancilla B; Di Paolo T
Parkinsonism Relat Disord; 2011 May; 17(4):270-6. PubMed ID: 21315648
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Dekundy A; Gravius A; Hechenberger M; Pietraszek M; Nagel J; Tober C; van der Elst M; Mela F; Parsons CG; Danysz W
J Neural Transm (Vienna); 2011 Dec; 118(12):1703-16. PubMed ID: 21161716
[TBL] [Abstract][Full Text] [Related]
10. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
11. Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators.
Kubas H; Meyer U; Krueger B; Hechenberger M; Vanejevs M; Zemribo R; Kauss V; Ambartsumova R; Pyatkin I; Polosukhin AI; Abel U
Bioorg Med Chem Lett; 2013 Aug; 23(16):4493-500. PubMed ID: 23856046
[TBL] [Abstract][Full Text] [Related]
12. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Ko WK; Pioli E; Li Q; McGuire S; Dufour A; Sherer TB; Bezard E; Facheris MF
Mov Disord; 2014 May; 29(6):772-9. PubMed ID: 24610195
[TBL] [Abstract][Full Text] [Related]
13. Mavoglurant as a treatment for Parkinson's disease.
Petrov D; Pedros I; de Lemos ML; Pallàs M; Canudas AM; Lazarowski A; Beas-Zarate C; Auladell C; Folch J; Camins A
Expert Opin Investig Drugs; 2014 Aug; 23(8):1165-79. PubMed ID: 24960254
[TBL] [Abstract][Full Text] [Related]
14. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Aman A; Fox SH; Brotchie JM
J Pharmacol Exp Ther; 2012 Aug; 342(2):576-85. PubMed ID: 22619253
[TBL] [Abstract][Full Text] [Related]
15. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
16. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.
Stepan AF; Claffey MM; Reese MR; Balan G; Barreiro G; Barricklow J; Bohanon MJ; Boscoe BP; Cappon GD; Chenard LK; Cianfrogna J; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Ghosh S; Hou X; Houle C; Karki K; Lazzaro JT; Mancuso JY; Marcek JM; Miller EL; Moen MA; O'Neil S; Sakurada I; Skaddan M; Parikh V; Smith DL; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Won A; Wright AS; Whritenour J; Zasadny K; Zaleska MM; Zhang L; Shaffer CL
J Med Chem; 2017 Sep; 60(18):7764-7780. PubMed ID: 28817277
[TBL] [Abstract][Full Text] [Related]
18. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
19. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Ouattara B; Grégoire L; Morissette M; Gasparini F; Vranesic I; Bilbe G; Johns DR; Rajput A; Hornykiewicz O; Rajput AH; Gomez-Mancilla B; Di Paolo T
Neurobiol Aging; 2011 Jul; 32(7):1286-95. PubMed ID: 20036444
[TBL] [Abstract][Full Text] [Related]
20. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes.
de Paulis T; Hemstapat K; Chen Y; Zhang Y; Saleh S; Alagille D; Baldwin RM; Tamagnan GD; Conn PJ
J Med Chem; 2006 Jun; 49(11):3332-44. PubMed ID: 16722652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
